A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : DOX

Search Conditions:
Search Keyword : DOX
Search Method : Exact match.
Research Area:

Results:  
Hit abbr.: 2 kinds.
(Click one to see its hit entries.)

(Appearance freq, Descending)
Abbreviation: DOX
Appearance Frequency: 7154 time(s)
Long forms: 100

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
doxorubicin
(6647 times)
Pharmacology
(1301 times)
MDR (419 times)
P-gp (304 times)
ROS (232 times)
1979 Effects of daunorubicin and doxorubicin, free and associated with DNA, on hemopoietic stem cells.
doxorubicin hydrochloride
(286 times)
Chemistry
(78 times)
NPs (20 times)
MSNs (14 times)
TEM (14 times)
1986 Treatment of adenocarcinoma in the peritoneum of mice: chemoimmunotherapy with IL-2-stimulated cytotoxic lymphocytes as a model for treatment of minimal residual disease.
doxazosin
(26 times)
Vascular Diseases
(6 times)
ALF (4 times)
BP (4 times)
BPH (3 times)
1987 A 24-week multicenter double-blind study of doxazosin and hydrochlorothiazide in patients with mild to moderate essential hypertension.
doxepin
(23 times)
Pharmacology
(8 times)
AMI (8 times)
IMI (5 times)
DDOX (4 times)
1978 Doxepin kinetics.
copolymer-doxorubicin
(19 times)
Pharmacology
(7 times)
HPMA (10 times)
MW (2 times)
Ab (1 time)
1999 Pharmacokinetics of PK1 and doxorubicin in experimental colon tumor models with differing responses to PK1.
doxycycline hyclate
(9 times)
Veterinary Medicine
(2 times)
beta-CD (1 time)
GCF (1 time)
HPLC-UV (1 time)
2007 Intra-articular administration of doxycycline in calves.
dioxygenase
(8 times)
Biochemistry
(5 times)
AOS (2 times)
bph (2 times)
LDS (2 times)
1994 Construction of hybrid biphenyl (bph) and toluene (tod) genes for functional analysis of aromatic ring dioxygenases.
doxorubicin HCl
(7 times)
Pharmacology
(2 times)
PLLA (2 times)
CEL (1 time)
CNTs (1 time)
2010 Mannosylated solid lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug.
docetaxel
(6 times)
Biochemistry
(2 times)
3'-UTRs (1 time)
AICP (1 time)
BCa (1 time)
2009 Weekly administration of docetaxel and epirubicin as first-line treatment for hormone-refractory prostate carcinoma.
10  docetaxel plus oxaliplatin and capecitabine
(4 times)
Neoplasms
(2 times)
ORR (2 times)
CR (1 time)
DCF (1 time)
2010 [Efficacy and safety evaluation of docetaxel plus oxaliplatin and capecitabine in the treatment of advanced gastric adenocarcinoma: a single center non-controlled phase II clinical trial].
11  drug-doxorubicin
(4 times)
Pharmacology
(2 times)
CNTs (1 time)
DTX (1 time)
EPR (1 time)
2007 Antitumor activity of new liposomal prodrug of mitomycin C in multidrug resistant solid tumor: insights of the mechanism of action.
12  10-dioxygenases
(3 times)
Biochemistry
(2 times)
AOS (3 times)
8R-DOX-LDS (1 time)
9R-HPODE (1 time)
2016 Replacement of two amino acids of 9R-dioxygenase-allene oxide synthase of Aspergillus niger inverts the chirality of the hydroperoxide and the allene oxide.
13  doxazosin mesylate
(3 times)
Biochemistry
(2 times)
ALF (1 time)
FIA (1 time)
HPLC (1 time)
2002 Flow injection analysis of doxazosin mesylate using UV-detection.
14  doxycycline gel
(3 times)
Dentistry
(2 times)
SRP (2 times)
Aa (1 time)
CAL (1 time)
2005 Non-surgical periodontal therapy with adjunctive topical doxycycline: a double-masked, randomized, controlled multicenter study. II. Microbiological results.
15  doxycycline hydrochloride
(3 times)
Pharmacology
(1 time)
FasL (1 time)
rtTA (1 time)
VSMCs (1 time)
2000 Expression of wild-type and noncleavable Fas ligand by tetracycline-regulated adenoviral vectors to limit intimal hyperplasia in vascular lesions.
16  doxylamine succinate
(3 times)
Pharmacy
(1 time)
PYR (2 times)
RP-HPLC (2 times)
FA (1 time)
1999 Simultaneous determination of pyridoxine hydrochloride and doxylamine succinate from tablets by ion pair reversed-phase high-performance liquid chromatography (RP-HPLC).
17  pectin-doxorubicin
(3 times)
Pharmacology
(2 times)
BC2Tama (1 time)
DOXPCB (1 time)
GI (1 time)
2018 Effect of lutein and doxorubicin combinatorial therapy on S180 cell proliferation and tumor growth.
18  (5,5-(2)H(2))-deoxy-d-xylose
(2 times)
Chemistry
(2 times)
enantio-MDGC-MS (1 time)
SBSE (1 time)
2002 Differential incorporation of 1-deoxy-D-xylulose into (3S)-linalool and geraniol in grape berry exocarp and mesocarp.
19  1,4-dioxane
(2 times)
Chemistry
(1 time)
cryo-TEM (1 time)
DLS (1 time)
PAPy (1 time)
2008 Effect of organic solvents on J aggregation of pseudoisocyanine dye at mica/water interfaces: morphological transition from three-dimension to two-dimension.
20  acute-doxorubicin
(2 times)
Cardiology
(1 time)
EPC (1 time)
HCC (1 time)
TPO (1 time)
2011 Thrombopoietin protects against doxorubicin-induced cardiomyopathy, improves cardiac function, and reversely alters specific signalling networks.
21  diiron carboxylate quinol oxidase
(2 times)
Biochemistry
(2 times)
AOX (1 time)
PTOX (1 time)
2003 Prokaryotic origins for the mitochondrial alternative oxidase and plastid terminal oxidase nuclear genes.
22  DOX loaded chitosan/carboxymethyl chitosan nanogels
(2 times)
Biochemistry
(1 time)
GI (1 time)
MMS (1 time)
P-gp (1 time)
2017 Multilayer micro-dispersing system as oral carriers for co-delivery of doxorubicin hydrochloride and P-gp inhibitor.
23  doxanthrine
(2 times)
Psychopharmacology
(2 times)
AUC (1 time)
DHX (1 time)
PD (1 time)
2009 Comparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptors.
24  doxantrazole
(2 times)
Gastroenterology
(2 times)
FAE (2 times)
CRH-R (1 time)
HRP (1 time)
2010 Stress-induced barrier disruption of rat follicle-associated epithelium involves corticotropin-releasing hormone, acetylcholine, substance P, and mast cells.
25  doxapram
(2 times)
Perinatology
(1 time)
Alm (1 time)
CSN (1 time)
GLUT (1 time)
1994 In vivo release of glutamate in nucleus tractus solitarii of the rat during hypoxia.
26  Doxepin hydrochloride
(2 times)
Anatomy
(1 time)
ASM (2 times)
Cer (2 times)
ABR (1 time)
2017 Doxepin Mitigates Noise-induced Neuronal Damage in Primary Auditory Cortex of Mice via Suppression of Acid Sphingomyelinase/Ceramide Pathway.
27  doxifluridine
(2 times)
Chemistry
(1 time)
5-FU (2 times)
ATA (1 time)
BEL (1 time)
1998 Enhancing effect of N-dodecyl-2-pyrrolidone on the percutaneous absorption of 5-fluorouracil derivatives.
28  doxorubicin base
(2 times)
Nanotechnology
(1 time)
CMC (1 time)
CSO (1 time)
CSO-LA (1 time)
2011 Linoleic acid-grafted chitosan oligosaccharide micelles for intracellular drug delivery and reverse drug resistance of tumor cells.
29  doxorubicin-based chemotherapy
(2 times)
General Surgery
(1 time)
CD (1 time)
CHF (1 time)
DLBCL (1 time)
2004 The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma.
30  doxorubicin-induced
(2 times)
Medicine
(1 time)
DOX group (1 time)
HE (1 time)
HO-1 (1 time)
2011 Prostacyclin administration as a beneficial supplement to the conventional cancer chemotherapy.
31  HA-doxorubicin
(2 times)
Pharmacology
(1 time)
ACC (1 time)
HA (1 time)
HPMA (1 time)
2002 Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.
32  (DSPE)-doxorubicin
(1 time)
Biomedical Engineering
(1 time)
DSPE (1 time)
DSPE-mPEG2000 (1 time)
Tet (1 time)
2017 Hybrid Prodrug Nanoparticles with Tumor Penetration and Programmed Drug Activation for Enhanced Chemoresistant Cancer Therapy.
33  2,5-dimethoxyamphetamines
(1 time)
Chemistry Techniques, Analytical
(1 time)
CID (1 time)
NLFs (1 time)
NPS (1 time)
2017 Characterization of hallucinogenic phenethylamines using high-resolution mass spectrometry for non-targeted screening purposes.
34  agent--doxorubicin
(1 time)
Medicine
(1 time)
gamma-GCS (1 time)
HaCaT (1 time)
MDR (1 time)
2013 Purine nucleoside analog--sulfinosine modulates diverse mechanisms of cancer progression in multi-drug resistant cancer cell lines.
35  alpha'-dimercapto-o-xylene
(1 time)
Toxicology
(1 time)
BDT (1 time)
DDOX (1 time)
DMPA (1 time)
1990 Structural influences on intracellular cadmium mobilization by dithiols.
36  An-PEG-DOX-AuNPs, was loaded with doxorubicin
(1 time)
Biomedical Engineering
(1 time)
LRP1 (1 time)
2015 Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles.
37  analogs--doxorubicin
(1 time)
Biology
(1 time)
ACR (1 time)
1998 Structurally different anthracyclines provoke different effects on cell cycle and tumor B cell differentiation.
38  anthracycline-doxorubicin
(1 time)
Pharmacology
(1 time)
CTAB (1 time)
LDL (1 time)
PEI (1 time)
2015 Low-density lipoprotein peptide-combined DNA nanocomplex as an efficient anticancer drug delivery vehicle.
39  BR96-doxorubicin
(1 time)
Antineoplastic Agents
(1 time)
--- 1997 Disposition of conjugate-bound and free doxorubicin in tumor-bearing mice following administration of a BR96-doxorubicin immunoconjugate (BMS 182248).
40  cisplatin-doxorubicin
(1 time)
Carbohydrates
(1 time)
--- 2017 Cisplatin-crosslinked glutathione-sensitive micelles loaded with doxorubicin for combination and targeted therapy of tumors.
41  cycler-doxorubicin
(1 time)
Chemistry
(1 time)
FA (1 time)
TPP (1 time)
2012 Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes.
42  deoxy-D-xylulose
(1 time)
Medicine
(1 time)
--- 1999 Induced biosynthesis of insect semiochemicals in plants.
43  deoxycholate
(1 time)
Cell Biology
(1 time)
--- 1975 [Some properties of preparations of Na+ and k+-ATPase treated with deoxycholate].
44  deoxyglucose
(1 time)
Obstetrics
(1 time)
AIB (1 time)
Cd (1 time)
VitB12 (1 time)
1984 Effects of cadmium on the placental uptake and transport to the fetus of nutrients.
45  desferrioxamine
(1 time)
Biochemistry
(1 time)
5 alpha-OOH (1 time)
BHT (1 time)
1988 Ascorbate-enhanced lipid peroxidation in photooxidized cell membranes: cholesterol product analysis as a probe of reaction mechanism.
46  develop functional Eu/MBGs by combining excellent apatite-mineralization ability, controllable drug
(1 time)
--- 2018 Design and Evaluation of Europium Containing Mesoporous Bioactive Glass Nanospheres: Doxorubicin Release Kinetics and Inhibitory Effect on Osteosarcoma MG 63 Cells.
47  developed a heterogeneous oxidant, i.e., a solid redox polymer
(1 time)
Biology
(1 time)
BV (1 time)
NOMs (1 time)
2017 Highly efficient and environmentally benign As(III) pre-oxidation in water by using a solid redox polymer.
48  Dewar- o-xylylene
(1 time)
Chemistry
(1 time)
PDOX (1 time)
POX (1 time)
2018 Polymer Valence Isomerism: Poly(Dewar- o-xylylene)s.
49  dexamethasone-oxetanone
(1 time)
Biochemistry
(1 time)
HTC (1 time)
TAT (1 time)
1986 Analysis of the relation between receptor binding affinity and antagonist efficacy of antiglucocorticoids.
50  dicloxacillin
(1 time)
Biochemistry
(1 time)
AMP (1 time)
CL (1 time)
OX (1 time)
2017 Radical-scavenging activity of penicillin G, ampicillin, oxacillin, and dicloxacillin.
51  dioxyxylene
(1 time)
Biochemistry
(1 time)
--- 2000 Polymer-supported and chemoenzymatic synthesis of the Neisseria meningitidis pentasaccharide: a methodological comparison.
52  diphenol oxidase
(1 time)
Molecular Biology
(1 time)
POx (1 time)
1991 Drosophila melanogaster diphenol oxidase A2: gene structure and homology with the mouse mast-cell tum- transplantation antigen, P91A.
53  dissolved oxygen multi-electrode sensor
(1 time)
Biotechnology
(1 time)
PCA (1 time)
2007 Detection and identification of bacteria using antibiotic susceptibility and a multi-array electrochemical sensor with pattern recognition.
54  DMSP-amine oxidase
(1 time)
Physiology
(1 time)
DMSP (1 time)
DMSP-amine (1 time)
SDC (1 time)
2000 Biochemical evidence for two novel enzymes in the biosynthesis of 3-dimethylsulfoniopropionate in Spartina alterniflora.
55  DNA origami/doxorubicin
(1 time)
Biocompatible Materials
(1 time)
--- 2018 Time-lapse live cell imaging to monitor doxorubicin release from DNA origami nanostructures.
56  docking, ONIOM, and XO
(1 time)
Chemistry
(1 time)
--- 2017 Structure-Based Rational Design of Novel Inhibitors Against Fructose-1,6-Bisphosphate Aldolase from Candida albicans.
57  DOX by confocal microscopy and fluorescence spectrophotometry showed that M-MSN
(1 time)
Biomedical Engineering
(1 time)
FA (1 time)
2016 Folate-Functionalized Magnetic-Mesoporous Silica Nanoparticles for Drug/Gene Codelivery To Potentiate the Antitumor Efficacy.
58  DOX combined with olaratumab (OLA)
(1 time)
Biochemistry
(1 time)
PAL (2 times)
PAZ (2 times)
DOC (1 time)
2019 Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model.
59  DOX concentration
(1 time)
Chemistry Techniques, Analytical
(1 time)
ECS (1 time)
2017 A general strategy to facilely design ratiometric electrochemical sensors in electrolyte solution by directly using a bare electrode for dual-signal sensing of analytes.
60  DOX release from pRGO@MS
(1 time)
Biomedical Engineering
(1 time)
DA (1 time)
GO (1 time)
HA (1 time)
2017 Mesoporous Silica Coated Polydopamine Functionalized Reduced Graphene Oxide for Synergistic Targeted Chemo-Photothermal Therapy.
61  DOX release from YSPMOs
(1 time)
Nanotechnology
(1 time)
CuS (1 time)
PTT (1 time)
YSPMOs (1 time)
2018 Fabrication of multifunctional triple-responsive platform based on CuS-capped periodic mesoporous organosilica nanoparticles for chemo-photothermal therapy.
62  DOX treated
(1 time)
Antineoplastic Agents
(1 time)
US (1 time)
2008 Combination of doxorubicin and low-intensity ultrasound causes a synergistic enhancement in cell killing and an additive enhancement in apoptosis induction in human lymphoma U937 cells.
63  DOX was released from HA-HMCN
(1 time)
Nanotechnology
(1 time)
GQD (1 time)
HA (1 time)
HMCN (1 time)
2018 Graphene quantum dots-gated hollow mesoporous carbon nanoplatform for targeting drug delivery and synergistic chemo-photothermal therapy.
64  DOX-DCMs
(1 time)
Nanotechnology
(1 time)
AUC (1 time)
NAC (1 time)
2018 Reversibly disulfide cross-linked micelles improve the pharmacokinetics and facilitate the targeted, on-demand delivery of doxorubicin in the treatment of B-cell lymphoma.
65  DOX-HAP
(1 time)
Neoplasms
(1 time)
DOX-HAP (1 time)
HAP (1 time)
1993 Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer.
66  DOX-loaded CS/CMCS nanoparticles
(1 time)
Chemistry
(1 time)
CMCS (1 time)
CS (1 time)
2013 Chitosan/o-carboxymethyl chitosan nanoparticles for efficient and safe oral anticancer drug delivery: in vitro and in vivo evaluation.
67  DOX-loaded PGMNs
(1 time)
Pharmacology
(1 time)
PGMNs (2 times)
2011 PEG-modified GoldMag nanoparticles (PGMNs) combined with the magnetic field for local drug delivery.
68  DOX-treated mice
(1 time)
Cachexia
(1 time)
sACVR2B-Fc (1 time)
2018 Prevention of chemotherapy-induced cachexia by ACVR2B ligand blocking has different effects on heart and skeletal muscle.
69  Doxacurium
(1 time)
Anesthesiology
(1 time)
CABG (1 time)
HR (1 time)
MAP (1 time)
1994 Hemodynamic and pharmacodynamic comparison of doxacurium and high-dose vecuronium during coronary artery bypass surgery: a cost-benefit study.
70  doxercalciferol
(1 time)
Endocrinology
(1 time)
--- 2018 Doxercalciferol Alleviates Bone Deteriorations and Cartilage Degeneration in Aging Mice.
71  doxorubicin (DOX)
(1 time)
Biochemistry
(1 time)
PAL (2 times)
PAZ (2 times)
DOC (1 time)
2019 Gemcitabine combined with docetaxel precisely regressed a recurrent leiomyosarcoma peritoneal metastasis in a patient-derived orthotopic xenograft (PDOX) model.
72  Doxorubicin activity
(1 time)
Medicine
(1 time)
--- 2006 [Pharmacological mechanisms of Doxorubicin activity (DOX) - current state of knowledge].
73  doxorubicin HCl liposomal injection
(1 time)
Pharmacology
(1 time)
HCC (1 time)
MB (1 time)
UTMD (1 time)
2015 Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model.
74  doxorubicin hydrochloride drug molecules
(1 time)
Natural Science Disciplines
(1 time)
FTIR (1 time)
PL (1 time)
SDNA (1 time)
2015 Chemical and Physical Characteristics of Doxorubicin Hydrochloride Drug-Doped Salmon DNA Thin Films.
75  doxorubicin hydrochloride:paclitaxel
(1 time)
Nanotechnology
(1 time)
ACMF (1 time)
MMNPs (1 time)
2015 Enhanced cell apoptosis triggered by a multi modal mesoporous amphiphilic drug delivery system.
76  doxorubicin in the free base form
(1 time)
Biomedical Engineering
(1 time)
DLS (1 time)
GPC (1 time)
MPEG (1 time)
2009 Folate-conjugated amphiphilic hyperbranched block copolymers based on Boltorn H40, poly(L-lactide) and poly(ethylene glycol) for tumor-targeted drug delivery.
77  doxorubicin or adriamycin
(1 time)
Biophysics
(1 time)
SERS (1 time)
THP-ADM (1 time)
1991 Selective analysis of antitumor drug interaction with living cancer cells as probed by surface-enhanced Raman spectroscopy.
78  Doxorubicin was administered alone
(1 time)
Cell Biology
(1 time)
--- 2012 The redox imbalance and the reduction of contractile protein content in rat hearts administered with L-thyroxine and Doxorubicin.
79  doxorubicin without dexrazoxane
(1 time)
Neoplasms
(1 time)
AR (1 time)
DOX/DZX (1 time)
SAECG (1 time)
2001 Signal-averaged electrocardiography in survivors of Hodgkin's disease treated with and without dexrazoxane.
80  doxorubicin, either in its traditional
(1 time)
Neoplasms
(1 time)
ACH (1 time)
AUC (1 time)
CHF (1 time)
2008 The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines.
81  Doxorubicin, PEG-LP
(1 time)
Chemistry
(1 time)
ECM (1 time)
EPR (1 time)
PEG-LP (1 time)
2016 Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
82  doxorubicin--conventional
(1 time)
Physiology
(1 time)
4-HNE (1 time)
ALDH3A1 (1 time)
TXNRD2 (1 time)
2015 Different doxorubicin formulations affect plasma 4-hydroxy-2-nonenal and gene expression of aldehyde dehydrogenase 3A1 and thioredoxin reductase 2 in rat.
83  doxorubicin-induced cardiomyopathy
(1 time)
Medicine
(1 time)
ICMP (1 time)
SHAM (1 time)
TAC (1 time)
2009 Myocardial protective effect of tezosentan, an endothelin receptor antagonist, for ischemia-reperfusion injury in experimental heart failure models.
84  doxorubicin-intercalated ZrP
(1 time)
Nanotechnology
(1 time)
AFM (1 time)
NPs (1 time)
SBF (1 time)
2013 Zirconium phosphate nanoplatelets: a biocompatible nanomaterial for drug delivery to cancer.
85  doxorubicin-resistant cells
(1 time)
Biochemistry
(1 time)
ANT (1 time)
mPTP (1 time)
VDACs (1 time)
2019 Rhein reverses doxorubicin resistance in SMMC-7721 liver cancer cells by inhibiting energy metabolism and inducing mitochondrial permeability transition pore opening.
86  Doxorubicin:Resveratrol
(1 time)
Chemistry
(1 time)
CI (1 time)
P-gp (1 time)
2018 Comparative study of the therapeutic effect of Doxorubicin and Resveratrol combination on 2D and 3D (spheroids) cell culture models.
87  doxycycline alone
(1 time)
Dentistry
(1 time)
TCP (1 time)
1989 The effect of local doxycycline with and without tricalcium phosphate on the regenerative healing potential of periodontal osseous defects in dogs.
88  Doxycycline monohydrate
(1 time)
Fe (1 time)
TC (1 time)
2017 Application of Metal-Organic Framework Nano-MIL-100(Fe) for Sustainable Release of Doxycycline and Tetracycline.
89  drugs-the pro-oxidative anthracyclines doxorubicin
(1 time)
Cell Biology
(1 time)
ACL (1 time)
ESR (1 time)
MTX (1 time)
1999 Changes in plasma membrane fluidity of immortal rodent cells induced by anticancer drugs doxorubicin, aclarubicin and mitoxantrone.
90  dual oxidant system
(1 time)
Environmental Health
(1 time)
US/DOX (1 time)
2013 Treatment of pharmaceutical effluent by ultrasound coupled with dual oxidant system.
91  gold-doxorubicin
(1 time)
Biotechnology
(1 time)
MDR (1 time)
2012 Gold-doxorubicin nanoconjugates for overcoming multidrug resistance.
92  linker-doxorubicin
(1 time)
Biomedical Engineering
(1 time)
DDSs (1 time)
SA (1 time)
SPDD (1 time)
2018 Sialic Acid-Functionalized pH-Triggered Micelles for Enhanced Tumor Tissue Accumulation and Active Cellular Internalization of Orthotopic Hepatocarcinoma.
93  nanoparticles-doxorubicin
(1 time)
Chemistry
(1 time)
MOA (1 time)
2019 Spontaneously formed porous structure and M1 polarization effect of Fe3O4 nanoparticles for enhanced antitumor therapy.
94  P(MAA-co-CMA)-doxorubicin
(1 time)
Biocompatible Materials
(1 time)
CDE (1 time)
CIE (1 time)
DLS (1 time)
2015 The endocytic pathway and therapeutic efficiency of doxorubicin conjugated cholesterol-derived polymers.
95  PEGylated-doxorubicin
(1 time)
Chemical Phenomena
(1 time)
DOXHCl (1 time)
IS (1 time)
LLE (1 time)
2018 Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles.
96  POEAd-C3-doxorubicin
(1 time)
Biochemistry
(1 time)
POEAd-C (1 time)
2017 Well-Defined Poly(Ortho Ester Amides) for Potential Drug Carriers: Probing the Effect of Extra- and Intracellular Drug Release on Chemotherapeutic Efficacy.
97  Poly(organophosphazene)-doxorubicin
(1 time)
Biomedical Engineering
(1 time)
AMPEG 550 (1 time)
IleOEt (1 time)
2009 Doxorubicin-polyphosphazene conjugate hydrogels for locally controlled delivery of cancer therapeutics.
98  polydopamine-doxorubicin
(1 time)
Biomedical Engineering
(1 time)
CT (1 time)
NIR (1 time)
PA (1 time)
2017 Biopolymer-Drug Conjugate Nanotheranostics for Multimodal Imaging-Guided Synergistic Cancer Photothermal-Chemotherapy.
99  pullulan-doxorubicin
(1 time)
Biomedical Engineering
(1 time)
--- 2014 High drug loading pH-sensitive pullulan-DOX conjugate nanoparticles for hepatic targeting.
100  SPIO-Doxorubicin
(1 time)
Nanomedicine
(1 time)
BBB (1 time)
FUS (1 time)
MBs (1 time)
2016 Ultrasound/Magnetic Targeting with SPIO-DOX-Microbubble Complex for Image-Guided Drug Delivery in Brain Tumors.